News & Updates
Filter by Specialty:
Statin use may reduce mortality in early breast cancer
The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.
Statin use may reduce mortality in early breast cancer
19 Jun 2024
Physical activity substantially cuts cirrhosis risk in MASLD patients
A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Physical activity substantially cuts cirrhosis risk in MASLD patients
19 Jun 2024
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024
PANTHER 10-year data support tailored dose-dense adjuvant chemo for high-risk early breast cancer
Long-term data from the phase III PANTHER trial demonstrate improved breast cancer recurrence-free survival (BCRFS) with tailored dose-dense adjuvant chemotherapy as opposed to standard adjuvant chemo in individuals with high-risk early breast cancer.
PANTHER 10-year data support tailored dose-dense adjuvant chemo for high-risk early breast cancer
18 Jun 2024
Vaccine combo a promising therapy for hypertension
Combined treatment with ATRQβ-001 and ADRQβ-004 vaccines shows potential as a therapeutic strategy for hypertension management, according to the preliminary findings of a study.
Vaccine combo a promising therapy for hypertension
18 Jun 2024
Trastuzumab deruxtecan delivers long-term survival in HER2+ breast cancer
HER2-positive metastatic breast cancer (mBC) patients who had been treated with trastuzumab emtansine continue to enjoy survival benefits with trastuzumab deruxtecan (TD) relative to those who received treatment of physician’s choice (TPC), as shown by the updated results of the DESTINY-Breast (DB)-02 study. TD also boasts of a manageable safety profile, with no long-term toxicity.